Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system

Journal of Neuroimmunology

Volumn 94, Issue 1-2, 1999, Pages 1-14

  Cuzner, M L ^a   Opdenakker, G ^a  

^a NONE

Author keywords

Experimental autoimmune encephalomyelitis; Matrix metalloprotease; Multiple sclerosis; Plasminogen activator

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; DEMYELINATING DISEASE; DEMYELINATION; ENZYME ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; MYELINATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; COLLAGENASES; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXTRACELLULAR SPACE; HUMANS; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; PLASMINOGEN ACTIVATORS;

EID: 0033081796     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00241-0     Document Type: Review

References (111)

1. Anthony D.C., Ferguson B., Matyzak M.K., Muller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23:1997;406-415.
2. Anthony D.C., Miller K.M., Fearn S., Townsend M.J., Opdenakker G., Wells G.M.A., Clements J.M., Chandler S., Gearing A.J.H., Perry V.H. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87:1998;62-72.
3. Astrup T., Permin P.M. Fibrinolysis in the animal organism. Nature (London). 159:1947;681-682.
4. Belcher C., Fawthrop F., Bunning R., Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. 55:1996;230-236.
5. Bianchi E., Ferrero E., Fazioli F., Mangili F., Wang J., Bender J.R. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. Clin. Invest. 98:1996;1133-1141.
6. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:1995;728-735.
7. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour necrosis factor alfa from cells. Nature. 385:1997;729-733.
8. Bläser J., Triebel S., Reinke H., Tschesche H. Formation of a covalent Hg-Cys-bond during mercurial activation of PMNL procollagenase gives evidence of a cysteine-switch mechanism. FEBS Lett. 313:1992;59-61.
9. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today. 18:1997;415-417.
10. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., Tschesche H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 13:1994;1263-1269.
11. Brosnan C.F., Cammer W., Norton W.T., Bloom B.R. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature. 285:1980;235-237.
12. Bunning R.A.D., Crawford A., Richardson H.J., Opdenakker G., Van Damme J., Russell R.G.G. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochim. Biophys. Acta. 924:1987;473-482.
13. Cammer W., Bloom B.R., Norton W.T., Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc. Natl. Acad. Sci. USA. 75:1978;1554-1558.
14. Cannella B., Raine S.C. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
15. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Bone metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201:1995;223-226.
16. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Cur. Opin. Cell Biol. 9:1997;714-724.
17. Chen Z.L., Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 91:1997;917-925.
18. Clements J.M., Cossins J.A., Wells G.M.A., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J.H., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J. Neuroimmunol. 74:1997;85-94.
19. Cohen I.R., Mor F. On the regulation of EAE. Int. Rev. Immunol. 9:1993;243-249.
20. Cuzner M.L., Norton W.T. Biochemistry of demyelination. Brain Pathol. 6:1996;231-242.
21. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
22. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1996;1563-1571.
23. Dubois B., D'Hooghe M.B., De Lepeleire K., Ketelaer P., Opdenakker G., Carton H. Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Multiple Sclerosis. 4:1998;74-78.
24. Eeckhout Y., Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin, plasmin and kallikrein, and spontaneous activation. Biochem. J. 166:1977;21-31.
25. Faber-Elman A., Miskin R., Schwartz M. Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-α and interleukin-1β through similar signal transduction pathways. J. Neurochem. 65:1995;1524-1535.
26. Fabry Z., Raine C.S., Hart M.N. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today. 15:1994;218-224.
27. Fridman R., Toth M., Pena D., Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 55:1995;2548-2555.
28. Gay F.W., Drye T.J., Dick G.W.A., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain. 120:1997;1461-1483.
29. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other infammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
30. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36:1993;432-440.
31. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94:1994;2177-2182.
32. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 267:1992;4583-4591.
33. Gros J., Lapière C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA. 48:1962;1014-1122.
34. Gutowski N.J., Newcombe J., Cuzner M.L. Changes in extracellular matrix tenascins during glial scar formation in MS plaques. Neuropathol. Appl. Neurobiol. 24:1998;155.
35. Hafler D.A., Weiner H.L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144:1995;75-107.
36. Haurum J.S., Arsequell G., Lellouch A.C., Wong S.Y., Dwek R.A., McMichael A.J., Elliott T. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180:1994;739-744.
37. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
38. Hughes P.M., Wells G.M.A., Clements J.M., Gearing A.J.H., Redford E.J., Davies M., Smith K.J., Hughes R.A.C., Brown M.C., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain. 121:1998;481-494.
39. Jacobs L., Johnson K.P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 51:1994;1245-1251.
40. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M.A., Schweitzer T., Gearing A.J.H., Hartung H.-P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 121:1998;159-166.
41. Kieseier B.C., Clements J.M., Pischel H.B., Wells G.M.A., Miller K., Gearing A.J.H., Hartung H.P. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann. Neurol. 43:1998;427-434.
42. Kjeldsen L., Bjerrum O.W., Askaa J., Borregaard N. Subcellular localization and release of human neutrophil gelatinase, confirming the existence of separate gelatinase-containing granules. Biochem. J. 287:1992;603-610.
43. Lacraz S., Isler P., Vey E., Welgus H.G., Dayer J.-M. Direct contact between T Lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. 269:1994;22027-22033.
44. Lassmann H., Zimprich F., Rössler K., Vass K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. Rev. Neurol. 147:1991;763-781.
45. Lehmann P.V., Sercarz E.E., Forsthuber T., Dayan C.M., Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today. 14:1993;203-208.
46. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinase mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
47. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon Beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
48. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J.H., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
49. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
50. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
51. Masos T., Miskin R. Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. Mol. Brain Res. 35:1996;139-148.
52. Masos T., Miskin R. mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation. Mol. Brain Res. 47:1997;157-169.
53. Masure S., Proost P., Van Damme J., Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198:1991;391-398.
54. Masure S., Nys G., Fiten P., Van Damme J., Opdenakker G. Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur. J. Biochem. 218:1993;129-141.
55. Masure S., Paemen L., Van Aelst I., Fiten P., Proost P., Billiau A., Van Damme J., Opdenakker G. Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. Eur. J. Biochem. 244:1997;21-30.
56. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays. 14:1992;455-463.
57. Matyszak M.K., Perry V.H. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol. 69:1996;141-149.
58. Michaëlsson E., Malmstrom V., Reis S., Engstrom A., Burkhardt H., Holmdahl R. T cell recognition of carbohydrates on type II collagen. J. Exp. Med. 180:1994;745-749.
59. Montgomery A.M.P., Sabzervari H., Reisfelf R.A. Production and regulation of gelatinase B by human T-cells. Biochem. Biophys. Acta. 1176:1993;265-268.
60. Moonen G., Grau-Wagemans M.P., Selak I. Plasminogen activator system and neuronal migration. Nature. 289:1982;753-755.
61. Mori K., Dwek R.A., Downing A.K., Opdenakker G., Rudd P.A. The activation of type 1 and type 2 plasminogen by type I and type 2 tissue plasminogen activator. J. Biol. Chem. 270:1995;3261-3267.
62. Muir E., Due J.S., Fork-Seang J., Smith-Thomas L.C., Housden E.S., Rogers J., Fawcett J.W. Increased axon growth through astrocyte cell lines transfected with urokinase. Glia. 23:1998;24-34.
63. Murphy G., Docherty A.J.P. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell. Mol. Biol. 7:1992;120-125.
64. Murphy G., Cockett M.I., Stephens P.E., Smith B.J., Docherty A.J. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem. J. 248:1987;265-268.
65. Nakajima K., Tsuzaki N., Shimojo M., Hamanoue M., Kohsaka S. Microglia isolated from rat brain secret a urokinase-type plasminogen activator. Brain Res. 577:1992;285-292.
66. Norga K., Paemen L., Masure S., Dillen C., Heremans H., Billiau A., Carton H., Cuzner L., Olsson T., Van Damme J., Opdenakker G. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm. Res. 44:1995;529-534.
67. Ogata Y., Enghild J.J., Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J. Biol. Chem. 25:1992;3581-3584.
68. Okada Y., Harris E.D. Jr., Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem. J. 254:1988;731-741.
69. Opdenakker G., Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine. 4:1992;251-258.
70. Opdenakker G., Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol. Today. 15:1994;103-107.
71. Opdenakker G., Masure S., Grillet B., Van Damme J. Cytokine mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 10:1991;317-324.
72. Opdenakker G., Rudd P.M., Ponting C.P., Dwek R.A. Concepts and principles of glycobiology. FASEB J. 7:1993;1330-1337.
73. Opdenakker G., Rudd P.M., Wormald W., Dwek R.A., Van Damme J. Cells regulate the activities of cytokines by glycosylation. FASEB J. 9:1995;453-457.
74. Opdenakker G., Fibbe W.E., Van Damme J. The molecular basis of leukocytosis. Immunol. Today. 19:1998;182-189.
75. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:1994;55-63.
76. Paemen L., Martens E., Masure S., Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem. 234:1995;759-765.
77. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152:1998;729-741.
78. Proost P., De Wolf-Peeters C., Conings R., Opdenakker G., Billiau A., Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. J. Immunol. 150:1992;1000-1010.
79. Proost P., Van Damme J., Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192:1993;1175-1181.
80. Qian Z., Gilbert M.E., Colicos M.A., Kandel E.R., Kuhl D. Tissue plasminogen activator is induced as an immediate early gene during seizure, kindling and long-term potentiation. Nature. 361:1993;453-457.
81. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15:1996;1572-1582.
82. Romanic A.M., Madri J.A. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 4:1994;145-156.
83. Rosenberg G.A., Estrada E., Kelley R.O., Kornfeld M. Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci. Lett. 160:1993;117-119.
84. Rudd P.M., Dwek R.A. Glycosylation: heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32:1997;1-100.
85. Salvesen G.S., Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell. 91:1997;443-446.
86. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1996;61-65.
87. Sobel R.A. The extracellular matrix in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 57:1998;205-217.
88. Sobel R.A., Michael M.D., Chen M., Maeda A., Hinojoza J.R. Vitronectin and integrin vitronectin receptor localization in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 2:1995;202-213.
89. Steinman L. The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv. Immunol. 49:1991;357-379.
90. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270:1995;5331-5338.
91. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., William G., Yong V.W. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Am. Neurol. 40:1996;853-863.
92. Uhm J.H., Dooley N.P., Oh L.Y.S., Yong V.W. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia. 22:1998;53-63.
93. Van den Steen P., Rudd P.M., Dwek R.A., Opdenakker G. Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol. 33:1998;151-208.
94. Van den Steen P., Rudd P.M., Dwek R.A., Van Damme J., Opdenakker G. Cytokine and protease glycosylation as a regulatory mechanism in inflammation and autoimmunity. Adv. Exp. Med. Biol. 435:1998;133-143.
95. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87:1990;5578-5582.
96. Washington R.A., Burton J., Todd R.F., Newman W., Dragovic L., Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels form patients with multiple sclerosis. Ann. Neurol. 35:1994;89-97.
97. Washington R.A., Becher B., Balabanov R., Antel J., Dore-Duffy P. Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia. J. Neurosci. Res. 45:1996;392-399.
98. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., Chapman H.A. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
99. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., Linington C. Animal models. Ann. Neurol. 36:1994;S47-S53.
100. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:1997;439-442.
101. Werb Z., Mainardi C.L., Vater C.A., Harris E.D. Jr. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. New Engl. J. Med. 296:1977;1017-1023.
102. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:1989;17213-17221.
103. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
104. Woodroofe M.N., Cuzner M.L. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive ISH. Cytokine. 5:1993;583-588.
105. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:1995;695-705.
106. Wuyts A., Haelens A., Proost P., Lenaerts J.-P., Conings R., Opdenakker G., Van Damme J. Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J. Immunol. 14-57:1996;1736-1743.
107. Yao J., Harvath L., Gilbert D.L., Colton C.A. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 27:1990;36-42.
108. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. TINS. 21:1998;75-80.
109. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Ann. Rev. Immunol. 8:1990;579-621.
110. Zernicke R.F., Wohl G.R., Greenwald R.A., Moak S.A., Leng W., Golub L.M. Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J. Rheumatol. 24:1997;1324-1331.
111. Zhou N., Paemen L., Opdenakker G., Froyen G. Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (ScFv). FEBS Lett. 414:1997;562-566.